Skip to Content

Join the 'Linagliptin' group to help and get support from people like you.

Linagliptin News

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Saxenda, Glyburide, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes

Posted 11 Jun 2016 by Drugs.com

Ridgefield, Conn., and Indianapolis, May 31, 2016 – The U.S. Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults. Jentadueto XR, which is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), is the seventh new treatment from the Boehringer Ingelheim-Lilly Diabetes alliance to be approved by the FDA in the last five years. Jentadueto XR combines 2.5 mg or 5 mg of linagliptin with 1000 mg of metformin. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine. “Adults with type 2 diabetes are ... Read more

Related support groups: Diabetes, Type 2, Metformin, Diabetes Mellitus, Jentadueto, Linagliptin, Linagliptin/metformin

Cost of Insulin Rises Threefold in Just a Decade: Study

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Americans with diabetes who rely on insulin to keep their blood sugar levels in check are facing sticker shock: A new study finds the price of insulin has tripled in only 10 years. Moreover, since 2010, per-person spending on insulin in the United States was more than spending on all other diabetes drugs, the study found. "The cost of insulin has risen rapidly over the last few years," said study senior author Philip Clarke, a professor of health economics at the University of Melbourne in Australia. Clarke added there should be an assessment to see whether this price hike is justifiable in terms of improved clinical outcomes. One reason for the price climb, he said, is a switch from human insulins to analog insulins, which cost more but may offer additional benefits. Also, doctors are more apt to prescribe insulin for people with type 2 diabetes now, Clarke ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Diabetes, Type 1, Januvia, Glucophage, Novolog, Diabetic Neuropathy, Glipizide, Humalog, Insulin Resistance, Janumet, Diabetic Nerve Damage, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar

New Diabetes Cases Among Americans Drop for First Time in Decades: CDC

Posted 1 Dec 2015 by Drugs.com

TUESDAY, Dec. 1, 2015 – In a sign that Americans may finally be turning the corner in the fight against diabetes – and possibly obesity – federal health statistics released Tuesday show that the number of new cases of diabetes has dropped for the first time in decades. The decline wasn't sudden or dramatic. But, the number of new diabetes cases went from 1.7 million in 2009 to 1.4 million in 2014, according to the U.S. Centers for Disease Control and Prevention. "It seems pretty clear that incidence rates have now actually started to drop. Initially it was a little surprising because I had become so used to seeing increases everywhere we looked," CDC researcher Edward Gregg told The New York Times. The proportion of Americans with diabetes is still twice what it was in the early 1990s. And not every racial group has made strides against the blood sugar disease, which is often ... Read more

Related support groups: Diabetes, Type 2, Obesity, Metformin, Insulin, Weight Loss, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir

Too Many Seniors With Diabetes Are Overtreated, Study Suggests

Posted 29 Oct 2015 by Drugs.com

THURSDAY, Oct. 29, 2015 – When it comes to treating seniors with diabetes, new research suggests that doctors often don't cut back on medications, even when treatment goals are surpassed. The study found that when people had potentially dangerous low blood sugar levels, just 27 percent had their medicines decreased. And when blood pressure treatments lowered blood pressure levels too much, just 19 percent saw a reduction in their medications. "As people get older, the risks of overtreating become greater, and the benefits become shorter. We have to start emphasizing that more isn't always better," said study author Dr. Jeremy Sussman, an assistant professor of internal medicine at the University of Michigan in Ann Arbor and a primary care doctor at the Ann Arbor VA System. The findings were published online Oct. 26 in the journal JAMA Internal Medicine. Practice guidelines generally ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Glyburide, Saxenda, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

FDA Warns of Joint Pain Tied to Common Type 2 Diabetes Drugs

Posted 31 Aug 2015 by Drugs.com

FRIDAY, Aug. 28, 2015 – Use of a class of widely prescribed medications for type 2 diabetes is tied to severe joint pain in some patients, the U.S. Food and Drug Administration warned on Friday. The drugs – sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) and alogliptin (Nesina) – come from a newer class of medications called DPP-4 inhibitors. The drugs can be taken alone or used in conjunction with other diabetes drugs, such as metformin. DPP-4 inhibitors help fight type 2 diabetes by boosting the amount of insulin the body produces after each meal, when blood sugar levels are typically high. However, in a statement, the FDA said the medications "may cause joint pain that can be severe and disabling," and the agency "has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class." The FDA stressed that patients who take ... Read more

Related support groups: Diabetes, Type 2, Metformin, Januvia, Glucophage, Janumet, Pre-Diabetes, Onglyza, Diabetes Mellitus, Tradjenta, Glucophage XR, Sitagliptin, ActoPlus Met, Glumetza, Janumet XR, Glyburide/Metformin, Jentadueto, Avandamet, Glyxambi, Glucovance, Linagliptin

FDA Medwatch Alert: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain

Posted 28 Aug 2015 by Drugs.com

ISSUE: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. See the Drug Safety Communication for a complete list of all FDA-approved DPP-4 inhibitors. BACKGROUND: DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. These medicines are available as single-ingredient products and in combination with other diabetes medicines such as metformin. RECOMMENDATION: Patients should not stop taking their DPP-4 ... Read more

Related support groups: Diabetes, Type 2, Januvia, Janumet, Onglyza, Tradjenta, Sitagliptin, Janumet XR, Jentadueto, Glyxambi, Linagliptin, Oseni, Saxagliptin, Kombiglyze XR, Alogliptin, Nesina, Alogliptin/pioglitazone, Kazano, Metformin/Sitagliptin, Juvisync, Empagliflozin/linagliptin

Health Tip: Diabetes Can Take a Toll on Teeth and Mouth

Posted 10 Aug 2015 by Drugs.com

-- Diabetes, especially when uncontrolled, can cause damage to your mouth and teeth. The Mouthhealthy.org website says possible effects of diabetes on the teeth and mouth include: Dry mouth, due to decreased saliva production. Increased risk of cavities due to less saliva. Gingivitis, characterized by bleeding, inflamed gums. Difficulty tasting food. Slower healing of mouth wounds. Increased risk of infection. Among diabetic children. teeth emerging earlier than expected. Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Oral and Dental Conditions, Xerostomia, Lantus, Toothache, Diabetes, Type 1, Januvia, Glucophage, Novolog, Diabetic Neuropathy, Burning Mouth Syndrome, Glipizide, Humalog, Insulin Resistance, Janumet, Diabetic Nerve Damage, Aphthous Ulcer

People With Type 2 Diabetes Do Benefit From Blood Sugar Checks

Posted 5 Aug 2015 by Drugs.com

WEDNESDAY, Aug. 5, 2015 – Personalized blood sugar self-monitoring benefits people with type 2 diabetes even if they're not taking insulin, a new small study shows. Some experts have questioned the value of self-monitoring in this group, and many insurers – including Medicare – limit the reimbursement of blood sugar (glucose) testing strips to one a day for people with type 2 diabetes. This study included 11 people with type 2 diabetes who worked with the researchers to create personalized, structured self-monitoring blood glucose schedules. In most cases, self-monitoring twice a day was the most helpful in providing meaningful information about blood sugar levels. However, there was room for individualization based on a patient's type of lifestyle and needs. For example, a patient might check their blood sugar twice a day three days a week instead of once a day seven days a week, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Byetta, Saxenda, Glyburide, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

FDA Approves Glyxambi (empagliflozin and linagliptin) for Type 2 Diabetes

Posted 2 Feb 2015 by Drugs.com

RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 2, 2015 – The U.S. Food and Drug Administration (FDA) has approved Glyxambi (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments. Glyxambi is not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Glyxambi has not been studied in patients with a history of pancreatitis, and it is unknown if using Glyxambi increases the risk of developing pancreatitis in these patients. Glyxambi is the first and only diabetes treatment in the U.S. to combine the dual mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) i ... Read more

Related support groups: Diabetes, Type 2, Linagliptin, Empagliflozin

FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

Posted 14 Mar 2013 by Drugs.com

ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics. These findings were based on examination of a small number of pancreatic tissue specimens taken from patients after they died from unspecified causes. FDA has asked the researchers to provide the methodology used to collect and study these specimens and to provide the tissue samples so the Agency can further investigate potential pancreatic toxicity associated with the incretin mimetics. BACKGROUND: Drugs in the incretin mimetic class include exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin ... Read more

Related support groups: Diabetes, Type 2, Victoza, Januvia, Janumet, Byetta, Bydureon, Liraglutide, Tradjenta, Sitagliptin, Jentadueto, Exenatide, Linagliptin, Nesina, Oseni, Alogliptin, Alogliptin/pioglitazone, Kazano, Metformin/Sitagliptin, Simvastatin/sitagliptin, Linagliptin/metformin

FDA approves updated prescribing information for Tradjenta (linagliptin) tablets for add-on therapy to insulin in adults with type 2 diabetes

Posted 17 Aug 2012 by Drugs.com

RIDGEFIELD, Conn. and INDIANAPOLIS, August 17, 2012, 2012 /PRNewswire/ – Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin. Tradjenta is a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes, such as metformin, sulfonylurea, pioglitazone or insulin. Tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). The FDA's decision is based on data from a 52-week, phase 3 trial demonstrating the efficacy of Tradjenta in ... Read more

Related support groups: Tradjenta, Linagliptin

Newer 'Second-Line' Diabetes Drug May Outperform Older Meds

Posted 28 Jun 2012 by Drugs.com

THURSDAY, June 28 – A new drug for type 2 diabetes causes significantly less weight gain and may carry lower risks for hypoglycemia (low blood sugar), heart attack and stroke than standard medications, a new study indicates. Researchers in Germany noted that the new drug, linagliptin (Tradjenta), is intended for use in patients that do not fare well with metformin, the most common first-line drug used to treat the disease. Patients with type 2 diabetes may stop responding to metformin over time. Others who do not respond to metformin alone are given a second drug to help them maintain normal blood sugar levels. The researchers noted that which drug they should be prescribed is unclear. The researchers pointed out that most patients are prescribed a class of drugs called sulphonylureas to supplement metformin. However, these drugs can sometimes lead to hypoglycemia and weight gain, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glimepiride, Amaryl, Tradjenta, Glucophage XR, Glumetza, Linagliptin, Fortamet, Riomet

FDA Approves Jentadueto (linagliptin/metformin hydrochloride) for the Treatment of Adult Patients with Type 2 Diabetes

Posted 1 Feb 2012 by Drugs.com

RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ – Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. Jentadueto provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar. Linagliptin (5 mg, once-daily) is marketed in the U.S. as Tradjenta (linagliptin) tablets. Jentadueto is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. At the maximum dose, Jentadueto demonstrated placebo-corrected reductions in hemoglobin A(1c) (HbA(1c) or A1C) ... Read more

Related support groups: Diabetes, Type 2, Metformin, Linagliptin

Four Common Meds Send Thousands of Seniors to Hospital: CDC

Posted 23 Nov 2011 by Drugs.com

WEDNESDAY, Nov. 23 – An estimated 100,000 older Americans are hospitalized for adverse drug reactions yearly, and most of those emergencies stem from four common medications, a new study finds. The four types of medication – two for diabetes and two blood-thinning agents – account for two-thirds of those drug-related emergency hospitalizations. "Of the thousands of medications available to older patients, a small group of blood thinners and diabetes medications caused a high proportion of emergency hospitalizations for adverse drug events among elderly Americans," said lead study author Dr. Daniel Budnitz, director of the U.S. Centers for Disease Control and Prevention's medication safety program. Medications previously designated "high-risk" were implicated in only 1.2 percent of hospitalizations, the study found. Working with a nationally representative database, CDC researchers ... Read more

Related support groups: Metformin, Aspirin, Warfarin, Coumadin, Plavix, Insulin, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Clopidogrel, Janumet, Glyburide, Lantus Solostar, Levemir, Actos, Glimepiride, Amaryl

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Tradjenta

Linagliptin Patient Information at Drugs.com